Agios Pharmaceuticals (NASDAQ:AGIO) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

– FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND ® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal ...

Agios Pharmaceuticals has announced that the European Commission has granted orphan medicinal product designation to mitapivat, an oral small molecule pyruvate kinase (PK) activator, for the treatment ...

Non-small-cell lung cancer (NSCLC) accounts for up to 85% of all cases of lung cancer, which is the most frequent cause of cancer-related deaths worldwide. The need for effective treatments against ...